Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dynamic MRI evaluation of gemcitabine + Abraxane in pancreatic adenocarcinoma
2012-003592-19Phase 2Completed
- Sponsor
- Erasmus Hospital
- Start
- Oct 2012
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of nab-paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Erasmus Hospital. Primary endpoint: Dynamic tumor response rate. Started Oct 2012; status: completed.
02
Drugs
nab-paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2012-003592-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003592-19.